Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

• Status: Completed
• Trial end date: 2020-10-08
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate the safety and duration of effect following different doses of Botulinum Toxin A (NT 201) in the treatment of glabellar frown lines.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merz Pharmaceuticals GmbH
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Male or female subject 18 years or over.

• Moderate (score = 2) to severe (score =3) GFL at maximum frown as assessed by investigator on the 4-point FWS.

• Moderate (score = 2) to severe (score =3) GFL at maximum frown as assessed by subject on the 4-point FWS.

Exclusion Criteria:

• Previous treatment with Botulinum neurotoxin (BoNT) of any serotype in the facial area within the last 12 months before injection.

• Previous treatment with any facial cosmetic procedure (e.g., chemical peeling, photo rejuvenation, mesotherapy, photodynamic therapy, laser treatment, tattooing of eyebrows) in the glabellar area within the last 12 months before injection.

• Previous treatment with any biodegradable filler in the glabellar area within the last 12 months before injection.

• Inability to substantially reduce GFL by physically spreading them apart as assessed by the investigator.

• Excessively thick sebaceous skin or hypertrophic muscles in the upper third part of the face.

• Any surgery or scars in the glabellar area.

• Marked facial asymmetry.

• Eyelid ptosis.

• Marked brow ptosis and/or dermatochalasis.

• Ongoing severe or unstable medical conditions, e.g., systemic infection, or pulmonary disease, at the discretion of the investigator.